Group 1: Market Overview - The Hang Seng Index fell by 0.22%, down 56 points, closing at 25,773 points, while the Hang Seng Tech Index rose by 0.27% [1] - The early trading volume in the Hong Kong stock market reached 133.9 billion HKD [1] Group 2: Company Performances - Pop Mart (09992) surged by 2.88%, with new products selling out instantly and continued high growth in H1 performance [1] - China Duty Free Group (01880) soared over 5% following the opening of its first city duty-free store in Guangzhou, with multiple city stores entering the cultivation phase [1] - Genscript Biotech (01672) increased by 4.7%, as the company raised funds to enhance its weight loss drug development, with Citigroup suggesting attention on the upcoming ASC30 Phase II data [1] - China Gold International (02099) rose by 6.8%, reaching a new high, with core product output exceeding half of the annual guidance and significant expansion potential at the Jiamar mine [1] - Meitu (01357) saw an early gain of over 7%, officially entering the MSCI China Index, with Morgan Stanley optimistic about the company's long-term growth potential [1] - Innovent Biologics (02696) increased by 5.68% post-earnings, with ongoing internationalization strategy and overseas product profits more than doubling in H1 [1] - Angelalign Technology (06699) rose over 7%, with H1 net profit increasing by over 360%, and declared a special interim dividend of 0.46 HKD [1] - Oriental Selection (01797) fell over 7%, with annual net profit declining by 99.67%, while Goldman Sachs maintained a "sell" rating [1][2] Group 3: Financial Results - Kintor Pharmaceutical (01951) dropped by 5.97% post-earnings, reporting a loss of 1.04 billion CNY in H1, compared to a profit in the same period last year [2]

Group 1 - The core point of the article is that Gilead Sciences-B (01672) announced a share placement to raise funds for clinical trials related to obesity treatments, which has positively impacted its stock price [1] - Gilead plans to place 52.4 million shares at HKD 16.45 each, representing a discount of approximately 9.9% from the previous closing price, with net proceeds expected to be HKD 468 million [1] - Approximately 90% of the funds raised will be allocated to the development of subcutaneous and oral peptide candidates for obesity clinical trials [1] Group 2 - The controlling shareholder and founder, Wu Jinzi, will sell 52.4 million shares at HKD 16.45 each and subsequently subscribe to 28.82 million new shares, resulting in a cash-out of HKD 388 million [1] - Citigroup has highlighted the potential of Gilead's small molecule GLP-1 receptor agonist ASC30, with phase II data expected to be released in Q4 this year, which could serve as a key catalyst for the company [1] - Management has indicated that the safety data from the ASC30 phase II A group blind clinical trial has shown good performance with no cases of discontinuation, and a business development partnership for ASC30 is anticipated by mid-2026 [1]

Group 1 - The core point of the article is that Gilead Sciences (歌礼制药) is experiencing a stock price increase following the announcement of a share placement to fund clinical trials for obesity-related peptide drugs [1] - Gilead plans to place 52.4 million shares at HKD 16.45 each, representing a discount of approximately 9.9% from the previous closing price, with net proceeds expected to be HKD 468 million [1] - Approximately 90% of the funds raised will be allocated to the clinical trial development of subcutaneous and oral peptide candidates for obesity [1] Group 2 - The company's controlling shareholder, Wu Jinzi, will sell 52.4 million shares at HKD 16.45 and subsequently subscribe to 28.82 million new shares, resulting in a cash-out of HKD 388 million [1] - Citigroup has released a report highlighting Gilead's potential for its small molecule GLP-1 receptor agonist ASC30, with phase II data expected in Q4 of this year, which could serve as a key catalyst for the company [1] - Management has indicated that the safety data from the ASC30 phase II A group blind clinical trial has shown good performance with no cases of discontinuation, and a business development partnership for ASC30 is anticipated by mid-2026 [1] - Citigroup believes that other candidates like ASC47 and ASC50 have not yet been fully recognized by the market, and new data releases could provide potential upside [1]

Group 1 - Rongchang Biologics (09995.HK) increased by 7.44% [1] - Yongtai Biologics-B (06978.HK) rose by 5.69% [1] - Gilead Sciences-B (01672.HK) saw a gain of 4.41% [1] - Laika Pharmaceuticals-B (02105.HK) experienced a rise of 3.18% [1]

歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议,根据一般 授权配发及发行2882万股新股份。 ...

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认 购协议, 根据一般授权配发及发行2882万股新股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據一九三三年美國證券法（經修訂） 登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將 僅以招股章程的方式進行，該招股章程可向證券發行人或賣方取得，並載有發行人及管理層的 詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 1 認購所得款項用途 完成根據一般授權配售現有股份及補足認購新股份 獨家整體協調人及獨家配售代理 ݷ 茲提述歌禮製藥有限公司（「 ...

Group 1 - The biopharmaceutical ETF (159859) has seen a 3.23% increase, marking three consecutive days of gains, with a turnover of 6.1% and a transaction volume of 1.93 billion yuan [3] - The underlying index, the National Certificate Biopharmaceutical Index (399441), rose by 3.02%, with significant increases in constituent stocks such as Kangtai Biological (300601) up 8.40%, Iwubio (300357) up 8.02%, and WuXi AppTec (603259) up 6.36% [3] - Over the past week, the biopharmaceutical ETF (159859) has averaged daily transactions of 1.54 billion yuan, ranking first among comparable funds [3] Group 2 - As of August 22, the biopharmaceutical ETF (159859) has seen a scale increase of 97.48 million yuan over the past two weeks, leading among comparable funds [3] - The ETF has attracted a total of 19.77 million yuan in inflows over the last five trading days, indicating strong investor interest [3] - The latest margin buying amount for the biopharmaceutical ETF (159859) reached 17.98 million yuan, with a margin balance of 101 million yuan [3] Group 3 - The biopharmaceutical ETF (159859) has achieved a net value increase of 37.96% over the past year, ranking first among comparable funds [3] - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research [4] - The recent approval of 387 children's drugs and 147 rare disease drugs since the start of the 14th Five-Year Plan has effectively met the medication needs of key populations [4] Group 4 - The global GLP-1 market is expanding, presenting strategic opportunities for Chinese companies, with notable developments in drug pricing and clinical research [4] - Domestic companies like Songli Pharmaceutical are advancing their oral small molecule GLP-1 (ASC30) into clinical trials in the U.S., showing promising results in weight loss [4] - Heng Rui Pharmaceutical's HRS9531 has achieved positive results in phase III clinical trials, and more clinical data and commercial collaborations are expected to emerge [5] Group 5 - The biopharmaceutical ETF (159859) and its linked funds are the largest and most liquid products in their category, with the highest year-to-date growth [5] - The Tianhong Innovation Drug ETF (517380) is the only product tracking the Hang Seng and Shanghai-Hong Kong Innovation Drug Select 50 Index, providing comprehensive coverage of A-shares and Hong Kong stocks [5]

Group 1 - The report from Huaxin Securities indicates a significant increase in both the number and amount of transactions in the pharmaceutical sector in the first half of 2025, with global transaction numbers reaching 456, a year-on-year increase of 32%, and total upfront payments amounting to $11.8 billion, a staggering increase of 136% [1] - Chinese transactions contributed nearly 50% of the total transaction amount and over 30% of the transaction numbers, highlighting the growing recognition of Chinese companies in the global innovative drug market [1] - The report suggests focusing on companies such as Heng Rui Medicine, WuXi AppTec, and Zhongsheng Pharmaceutical due to their potential in the expanding market [1] Group 2 - The global GLP-1 market is experiencing stable expansion, with sales exceeding $33.6 billion in the first half of the year and expected to surpass $60 billion for the entire year [2] - Domestic companies like Goli Pharma are advancing their oral small molecule GLP-1 (ASC30) into clinical trials in the U.S., showing promising results in weight loss [2] - More clinical data and commercial collaborations are anticipated as companies like Heng Rui Medicine and Zhongsheng Pharmaceutical progress in their clinical trials [2] Group 3 - Multiple Chinese studies have been selected for major international conferences, indicating that Chinese innovative drug companies maintain a leading position in research and development, particularly in ADC and bispecific antibodies [3] Group 4 - The CXO industry is expected to gradually recover following a supply-side reshuffle, with leading companies like WuXi AppTec reporting a 24.2% year-on-year increase in revenue from continuing operations [4] - The order trend for the CXO industry is showing significant improvement, with a 37.2% year-on-year increase in orders, suggesting a broader recovery in the industry [4] Group 5 - The National Healthcare Security Administration has initiated the work on the 2025 medical insurance drug catalog and commercial health insurance innovative drug catalog, with 121 out of 141 drug names passing the preliminary review [5] - The focus on orphan drugs and breakthrough treatment varieties is evident, as these categories are among those that have passed the review process [5]